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Friedreich’s Ataxia (FRDA) is an autosomal recessive neurodegenerative disorder,
affecting dorsal root ganglia (DRG), cerebellar dentate nuclei and heart. It is caused
by a GAA repeat expansion mutation within the frataxin gene (FXN). This impedes
FXN transcription resulting in a progressive decrease of the mitochondrial protein,
frataxin. Increased oxidative stress leading to a chronic depletion of endogenous
antioxidants affects the survival of the cells and causes neurodegeneration. In particular,
cerebellar granule neurons (CGNs) show a significant increase of reactive oxygen
species (ROS), lipid peroxidation and lower level of reduced glutathione (GSH). In
FRDA, one of the major pathways of oxidant scavengers, the Nrf2 antioxidant pathway,
is defective. Previous studies on FRDA-like CGNs showed that the reduced level
of frataxin and the oxidative stress induce mitochondrial impairments. By triggering
the Nrf2 endogenous pathway pharmacologically we determined whether this could
promote mitochondrial fitness and counteract oxidative stress. In this work, we sought
to investigate the beneficial effect of a promising Nrf2-inducer, omaveloxolone (omav),
in CGNs from two FRDA mouse models, KIKO and YG8R, and human fibroblasts
from patients. We found that CGNs from both KIKO and YG8R presented Complex
I deficiency and that omav was able to restore substrate availability and Complex I
activity. This was also confirmed in human primary fibroblasts from FRDA patients.
Although fibroblasts are not the major tissue affected, we found that they show
significant differences recapitulating the disease; this is therefore an important tool to
investigate patients’ pathophysiology. Interestingly, we found that patient fibroblasts had
an increased level of endogenous lipid peroxidation and mitochondrial ROS (mROS),
and lower GSH at rest. Omav was able to reverse this phenotype, protecting the
cells against oxidative stress. By stimulating the cells with hydrogen peroxide (H2O2)
Abbreviations: ARE, antioxidant responsive elements; CCD, cooled charge-coupled device camera; DRG, dorsal root ganglia;
ETC, electron transport chain; FCCP, Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; FRDA, Friedreich’s Ataxia;
FXN, frataxin gene; GSH, reduced glutathione; GSK3, glycogen synthase kinase 3; GSTP1, Glutathione S-transferase P; H2O2,
hydrogen peroxide; Hrd1, E3 ubiquitin ligase synoviolin; ISCs, iron sulfur clusters; KEAP1, Kelch-like ECH-associated
protein 1; MCB, monochlorobimane; mROS, mitochondrial reactive oxygen species; NADH, Nicotinamide Adenine
Dinucleotide; NADPH, Nicotinamide Adenine Dinucleotide Phosphate Hydrogen; Nrf2, Nuclear factor (erythroid-derived
2)-like 2; omav, omaveloxolone; PI, propidium iodide; ROS, reactive oxygen species; SOD 2, superoxide dismutase 2;
SOD1, superoxide dismutase 1; TMRM, Tetramethyl rhodamine, methyl ester.
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and looking for potential mitochondrial pathophysiology, we found that fibroblasts
could not maintain their mitochondrial membrane potential (∆Ψm). Remarkably, omav
was protective to mitochondrial depolarization, promoting mitochondrial respiration and
preventing cell death. Our results show that omav promotes Complex I activity and
protect cells from oxidative stress. Omav could, therefore, be used as a novel therapeutic
drug to ameliorate the pathophysiology of FRDA.
Keywords: Friedreich’s ataxia, reactive oxygen species, lipid peroxidation, mitochondrial dysfunction, human
fibroblasts, nuclear factor (erythroid-derived 2)-like 2
INTRODUCTION
Friedreich’s Ataxia (FRDA) is a rare autosomal recessive
disorder. Patients develop dorsal root ganglia (DRG) and
dentate nucleate atrophy and cardiomyopathy (Parkinson
et al., 2013). The disease-causing mutation is harbored within
the frataxin gene (FXN), impeding the transcription of the
gene and resulting in a decrease of the final product, the
mitochondrial protein, frataxin (Campuzano et al., 1996).
Frataxin is crucial for the biogenesis of iron sulfur clusters
(ISCs; Radisky et al., 1999; Lesuisse et al., 2003; Martelli
and Puccio, 2014). Impairments of ISC biogenesis result
in accumulation of iron free radicals and lack of ISCs to
serve aconitase and complex I, II and III of the electron
transport chain (ETC) within the mitochondria (Al-Mahdawi
et al., 2006; Condò et al., 2010). Mitochondria are the sites
where the cell produces energy and generates reactive oxygen
species (ROS; Nickel et al., 2014). The pathogenic mechanism
triggered by the reduced production of frataxin leads to the
generation of oxidative stress, mitochondrial energy imbalance
and an increase in lipid peroxidation. This has been shown
in cerebellar granule neurons (CGNs), and mouse fibroblasts
(Abeti et al., 2015, 2016). In different models, fibroblasts
from patients showed a marked sensitivity to pro-oxidant
agents (Paupe et al., 2009; Shan et al., 2013). Indeed, human
fibroblasts have shown a defective Nuclear factor (erythroid-
derived 2)-like 2 (Nrf2) pathway, due to Nrf2 failure to
translocate from cytosol to nucleus (Paupe et al., 2009).
The Nrf2 pathway is one of the major antioxidant and
ROS scavenging pathways which defends the cells against
oxidative stress and regulates mitochondrial metabolism and
function (Esteras et al., 2016). In primary fibroblasts from
a FRDA-like mouse model, we found that Nrf2 inducers
were protective against the increase in lipid peroxidation,
mitochondrial energy imbalance and cell death (Abeti et al.,
2015). Amongst the therapeutic strategies applied to FRDA,
over the years, antioxidants have been shown to have a positive
outcome (Cooper and Schapira, 2007; Cooper et al., 2008).
In this work, we have investigated the beneficial effect on
oxidative stress and mitochondrial function of omaveloxolone
(omav) which specifically triggers the Nrf2 pathway (Creelan
et al., 2017). The turnover of Nrf2 is regulated through
ubiquitination and proteasomal degradation. Nrf2 is one of
the main components driving the transcription of antioxidant
responsive elements (ARE) in the presence of high levels of
oxidation in the cells. The proteins involved in Nrf2 regulation
are Kelch-like ECH-associated protein 1 (Keap1), which acts as
negative regulator of Nrf2 (Itoh et al., 1999); glycogen synthase
kinase 3 (GSK3), which phosphorylates Nrf2 and drives it
towards degradation via β-transducin repeats-containing protein
(β-TrCP-Cul1-based ubiquitin ligase); and E3 ubiquitin ligase
synoviolin (Hrd1), which takes part in protein degradation
in the endoplasmic reticulum (Wu et al., 2014). Omav is
a new Nrf2 activator that prevents the ubiquitination of
Nrf2, increasing its levels (Reisman et al., 2014a; Holmström
et al., 2016). In cellular models of FRDA, the Nrf2 pathway
seems to be suppressed and Nrf2 fails to undergo nuclear
translocation in cellular models of FRDA (Paupe et al., 2009).
Moreover, Nrf2 target proteins are also downregulated in
FRDA. We now investigated the effect of omav in CGNs
from two mouse models, KIKO and YG8R, and FRDA human
fibroblasts. We found that omav was able to protect the
cells from a marked Complex I inhibition as measured by
nicotinamide adenine dinucleotide (NADH) autofluorescence
and was able to increase the mitochondrial NADH pool and
activate respiration across models. Moreover, omav was able to
counteract oxidative stress, as detected by lipid peroxidation,
mitochondrial ROS (mROS) and reduced glutathione (GSH)
levels. By looking at the mitochondrial membrane potential
(∆Ψm), a marker of mitochondrial health, we found that FRDA
cells pre-treated with omav were able to maintain their ∆Ψm,
indicating its effect on oxidative stress had also a positive
impact on mitochondrial function. Finally, we found that this
compound was protective against hydrogen peroxide (H2O2)-
induced cell death in FRDA fibroblasts. This shows that omav
could potentially be used as a novel therapeutic drug in
FRDA, to ameliorate the pathophysiology of this impairing
disorder.
MATERIALS AND METHODS
Cerebellar Granule Neurons
CGNs from KIKO (mFxn−/+230 GAA; From Jackson Laboratory;
Marmolino et al., 2010) and YG8R mice (mFxn−/− and
hFXN−/+82 and 190GAA; From Jackson Laboratory; Al-Mahdawi
et al., 2006) and their controls, respectively WT and Y47R
(mFxn−/− and hFXN−/+9GAA; From Jackson Laboratory) were
isolated with the method described in Abeti et al. (2016)
with few modifications. In brief, cerebella were isolated and
homogenized and dissociated with 0.25% trypsin-EDTA (Sigma
Aldrich). CGNs were plated on, pre-coated with Poly-D-lysine
(1 mg/ml), glass coverslips. Cells were maintained in Neurobasal
with 2% of B27 (Invitrogen) and 2 mM L-glutamine, 1% of
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penicillin/streptomycin (Sigma Aldrich) and 25 mM KCL (to
keep the CGNs slightly depolarized; Scorziello et al., 1996). To
avoid glial proliferation 10 µM AraC was added after 24 h
from the plating. CGNs were used 7 days after plating. Cells
were maintained in a humidified incubator at 37◦C and at 5%
CO2. Prior experiments cells were treated 24 h with 50 nM
omav.
Primary Human Fibroblasts
Primary Human Fibroblasts were extracted from skin biopsy
samples from patients and control subjects (Table 1, Control,
Carrier, Patient 1 and 2). Fibroblasts were maintained in
Dulbecco’s Eagle Modified (DMEM) Glutamax (Invitrogen),
with 10% Foetal Bovine Serum (FBS; Invitrogen). Cells were
harvested with 0.25% trypsin-EDTA (Sigma Aldrich), then
inactivated with complete media and plated on 25 mm glass
coverslips or directly into a six multi-wells plate, according to the
type of experiment.
Lipid Peroxidation Measurements
Cells were loaded with 10 µM C11 BODIPY (581/591) for
10 min, which measures lipid peroxidation in the cell. The dye
was excited at 488 nm (oxidized form) and 561 nm (unoxidized
form; Abeti et al., 2015, 2016), detected with 710 Zeiss Confocal
VIS CLSM equipped with a META detection system and a 40×
oil immersion objective. The ratio of 488/561 nm was analyzed
and the rates were then calculated in ArbU/min.
Mitochondrial ROS
Cells were loaded with 1 µM MitoTracker Red CM-H2Xros
(Thermo Scientific) incubated for 20 min before the beginning
of the experiments, and then imaged the increase of fluorescence
over time using 561 nm excitation and long pass filter.
MitoTracker Red CM-H2Xros is a reduced, non-fluorescent dye
which fluoresces upon oxidation and enters the mitochondria
according to the membrane potential. Confocal images were
obtained using a Zeiss 710 VIS CLSM equipped with a META
detection system and a 40× oil immersion objective.
Measurement of ∆Ψm
Tetramethyl rhodamine, methyl ester (TMRM) is a cationic,
cell-permeant fluorescent dye readily sequestered by healthy
mitochondria. Basal mitochondrial membrane potential was
measured in the non-quench mode, loading the cells with
25 nM TMRM for 40 min, z-stacks were acquired with a
710 Zeiss Confocal microscope. To measure small differences in
the maintenance of ∆Ψm we used a de-quenching mode. Cells
TABLE 1 | Patients GAA repeats.
GAA repeats
Control N/A
Carrier N/A
Patient 1 850/1186
Patient 2 1000/1000
Control was unaffected; Carrier had one copy of the mutation. Patients GAA
repeats are indicated in the table.
were incubated for 20 min with 1 µM TMRM. Depolarization,
after oligomycin (2 µg/mL) administration, was detected
as an increase of ∆Ψm. At the end of each experiment,
1 µM Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone
(FCCP) was applied. FCCP is protonophore that dissipates the
potential completely. TMRM was visualized using an excitation
wavelength of 561 nmwith a long pass filter using a Zeiss 710 VIS
CLSM equipped with a META detection system and a 40× oil
immersion objective.
Glutathione Measurements
Reduced Glutathione (GSH) was measured with
monochlorobimane (MCB), a non-fluorescent compound
that becomes fluorescent when binds GSH. Cells were incubated
with 50 µM MCB for 30 min. Confocal images (z-stacks) were
acquired for quantitation using a Zeiss 710 VIS CLSM equipped
with a META detection system and a 40× oil immersion
objective.
NADH Pool and Redox State
The autofluorescence of NADH and NADPH (which can be
referred to NAD(P)H) in fibroblast cultures was imaged on
a cooled charge-coupled device (CCD) camera (Hamamatsu,
Orca ER). The blue autofluorescence, emitted by the pyridine
nucleotides NADH and NADPH in their reduced form, was
excited with a 360 nm and emission was collected using
a 455 nm filter. Confocal images were acquired using a
Zeiss 510 UV LSM system and a 63× water immersion
objective. The application of mitochondrial uncoupler 1 µM
FCCP maximizes the rate of respiration and oxidizes the
mitochondrial NADH pool in cells, resulting in a decrease
of detected fluorescence (minimum = 0% for NADH). The
subsequent application of the Complex IV inhibitor, 1 mM
NaCN, suppresses respiration preventing NADH oxidation and
allowing the NADH pool to be regenerated (maximum = 100%
for NADH). The final formula used to normalize the NADH
autofluorescence measurement was: ∆F − Ffccp/∆FNaCN −
Ffccp (Abeti et al., 2011). Quantitative analysis of the images
obtained was done cell by cell using the AQM Andor software,
the average was taken from n > 3 independent experiments for
each condition.
Cell Death
Cells were treated 24 h with 50 nM omav, 2 h with 1 mM H2O2.
Prior imaging, cells were incubated with propidium iodide (PI;
10 µM) and 300 nM DAPI for 15 min, washed 3× with PBS 1×
and analyzed using a cooled CCD camera. DAPI stains all nuclei
while PI stains only cells with a disrupted plasma membrane.
Dead fibroblasts (PI positive), were counted as a fraction of the
total. In each experiment, were examined five random fields and
the mean is representative of three independent experiments for
each condition.
Statistical Analysis
Statistical analysis was performed with Excel, Origin 9 (Microcal
Software Inc.) and GraphPad5 software (GraphPad Software,
La Jolla, CA, USA). Results are expressed as means ± S.E.M
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FIGURE 1 | Omaveloxolone (Omav) prevents Complex I inhibition in friedreich’s ataxia (FRDA) fibroblasts and neurons. (A) Representative trace of nicotinamide
adenine dinucleotide (NADH) autofluorescence where the basal level refers to the NADH redox state and the response to NaCN subtracting the response to carbonyl
cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) represents the NADH pool. (B–D) The histograms represent the calculation total NADH pool in KIKO, YG8R
cerebellar granule neurons (CGNs) and Patients compared to their controls and without/with omav (∗∗p < 0.005; ∗∗∗p < 0.0005). (E–G) The histograms represent the
calculation total NADH redox state in KIKO, YG8R CGNs and Patients compared to their controls and without/with omav (∗p < 0.05; ∗∗∗p < 0.0005).
or S.D.M. The ANOVA test was applied when appropriate and
the point of minimum acceptable statistical significance was
taken to be 0.05, and was Bonferroni corrected where required.
Representative averages were taken from n > 3 independent
experiments.
RESULTS
Complex I Inhibition Present Across FRDA
Models
In FRDA, the full function of the mitochondrial ETC is partially
impaired as the lack of frataxin inhibits the production of
ISCs which are crucial for the functional activity of Complex
I, II and III. Amongst the three Complexes, Complex I
requires more ISCs and is therefore more sensitive to changes
in frataxin level. By measuring NADH autofluorescence, we
could detect the levels of the mitochondrial NADH pool
available and also the NADH redox state to prove Complex
I deficiency and understand whether or not omav could
restore it. Figure 1 shows a representative trace of NADH
autofluorescence measurements in FRDA cells, and their
response to 1 µM FCCP and 1 mM NaCN (Figure 1A;
Bartolomé and Abramov, 2015). We found that the level of
NADH pool in CGNs from KIKO and YG8R mice was lower
compared to their controls and that 50 nM omav pre-incubated
for 24 h was able to restore it (Figures 1B,C; KIKO-UNTR
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FIGURE 2 | Oxidative stress in FRDA fibroblasts is prevented by omav. (A) Lipid peroxidation was measured in Control and FRDA cells with C11 BODIPY (581/591)
using live imaging over time. (B) The ratio of the fluorophore was calculated (488/562 nm) and analyzed the rate of increase in percentage (%; taken Control as
100%). Patient 1 and 2 fibroblasts untreated showed a significant increase compared to Control (∗∗∗p < 0.0005) and a significant decrease in rate after omav
compared to untreated cells (∗∗p < 0.005). (C) The curve shows the kinetic curve of CM-H2Xros generated by Control and FRDA cells. (D) The rate of increase was
expressed in ArbU/min. The rates in untreated patients’ cells were significantly increased compared to Control (∗p < 0.05) and patients’ cells untreated and treated
with omav showed a significant difference (Patient 1 ∗p < 0.05; Patient 2 ∗∗p < 0.005). (E) Glutathione (GSH) was measured with monochlorobimane (MCB) and
was lower in patients untreated compared to Control (∗∗∗p < 0.0005) and the amount seemed to be restored in patients’ cells treated with omav (∗p < 0.05).
46.5± 8.2, KIKO-omav 92.6± 9.8, ∗∗∗p< 0.0005; YG8R-UNTR
39.8 ± 14.4, ∗∗∗p < 0.0005, YG8R-omav 84 ± 5.5, ∗∗p < 0.005).
Similar results were achieved in FRDA patient’s fibroblasts.
Figure 1D shows the NADH pool in fibroblasts untreated
and challenged with a pro-oxidant (hydrogen peroxide; 1 mM
H2O2; Figure 1D; Patient 1 43.48 ± 7.8, Patient 1_H2O2
13.33 ± 3.8, Patient 1_omav_H2O2 107.8 ± 10.15, Patient 2
49.58 ± 1.08, Patient 2_H2O2 12.04 ± 2.3, Patient 2_
omav_H2O2 92.73 ± 12; ∗∗∗p < 0.0005). Across FRDA models
the NADH redox state was higher than controls and was
recovered by pre-treating them with omav (Figures 1E–G;
KIKO-UNTR 312 ± 45, KIKO-omav 124.3 ± 23, ∗∗∗p < 0.0005;
YG8R-UNTR 184.3 ± 3.1, YG8R-omav 126 ± 18, ∗p < 0.05;
Patient 1 257.3 ± 102.3, Patient 1_H2O2 315.5 ± 19.9, Patient
1_omav_H2O2 123.6 ± 24.1; Patient 2 219.8 ± 44.2, Patient
2_H2O2 303.3 ± 17.9, Patient 2_omav_H2O2 124.1 ± 13.17;
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FIGURE 3 | Omav protected ∆Ψm maintenance in stressed fibroblasts. (A) Basal ∆Ψm was measured with 25 nM tetramethyl rhodamine, methyl ester (TMRM).
Untreated and cells pre-treated with omav did not show significant differences. (B) We, therefore, treated patients’ fibroblasts with 1 mM H2O2 for 2 h and assessed
the maintenance of ∆Ψm with 1 µM TMRM (De-quencing mode) and challenged the cells with 2 µg/mL oligomycin. (C) The increase of TMRM after oligomycin
administration was then calculated in %. Patients’ cells showed a stable line if untreated, however, those treated with H2O2 showed a marked depolarization which
was significantly prevented with omav (∗∗p < 0.005).
∗p< 0.05). TheNADHpool decreases combined to an increase of
NADH redox state confirmed Complex I inhibition (Bartolomé
and Abramov, 2015). Thus, in FRDA models, the activation of
the Nrf2 pathway with omav is able to increase the availability
of substrates for Complex I and protect the mitochondrial
respiration, highlighting its beneficial role in mitochondrial
bioenergetics (Dinkova-Kostova et al., 2015; Bartolome et al.,
2017).
Omaveloxolone Prevents Oxidative Stress
in Fibroblasts From FRDA Patients
After confirming that Complex I inhibition is present across
FRDA models, we investigated further the omav’s efficacy by
assessing FRDA patient’s fibroblasts to confirm that they are
a good model for drug testing and potentially recapitulate
the disease. One of the markers for oxidative stress in FRDA
is lipid peroxidation (Barnham et al., 2004; Abeti et al.,
2015, 2016). Therefore, we first assessed the rate of lipid
peroxidation in two primary lines of human fibroblasts from
FRDA patients (Table 1) using C11 BODIPY (581/591). Patients’
fibroblasts showed a significant increase in lipid peroxidation
compared to control, already at steady state (Figures 2A,B).
In Figure 2A, we show the increase in fluorescence intensity
of C11 BODIPY (581/591) in a mean of experiments from
control and FRDA patients. In Figure 2B the histogram
represents the rate of the dye in percentage (normalized to
control) of patients’ fibroblasts with and without 50 nM
omav incubated for 24 h prior experiment. The rate of lipid
peroxidation was significantly increased in untreated patients
compared to control (Patient 1 183.4 ± 32.8; Patient 2
179.9 ± 43; ∗∗∗p < 0.0005) and by pre-treating cells with
omav the rates decreased significantly in patients (Patient
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FIGURE 4 | Omav prevents cell death in FRDA fibroblasts. Cells were stained
with DAPI for total cells counting and propidium iodide (PI) to visualize dead
cells. The % of dead cells was calculated for each case. Hydrogen peroxide
(H2O2) treated cells in red (Carrier, Patients 1 and 2) showed a % of cell death
greater than the Control. This was prevented by omav (∗∗∗p < 0.0005).
1_omav 130 ± 27, Patient 2_omav 110 ± 18; ∗∗p < 0.005),
demonstrating that omav can prevent the pathophysiological
increase of lipid peroxidation. We have previously shown that
in neurons from an FRDA mouse model, the levels of mROS
are also increased, due to lack of frataxin which generates
more free radicals and disrupts mitochondrial function (Abeti
et al., 2016). We then assessed mROS generation in patient
fibroblasts using MitoTracker Red CM-H2XRos. As shown in
Figures 2C,D, we found that the rate of mROS was increased,
and this was successfully prevented by omav (Figure 2D;
Control 0.155 ± 0.06, Patient 1 0.3128 ± 0.074; Patient 2
0.3248 ± 0.052; ∗p < 0.05; Patient 1_omav 0.135 ± 0.055;
Patient 1 untreated and treated ∗p < 0.05; Patient 2_omav
0.107 ± 0.013; Patient 2 untreated and treated ∗∗p < 0.05).
Interestingly, the carrier sample showed that the rate of mROS
was lower than the control. Considering that carriers are
asymptomatic but they have about 50% of frataxin levels
compared to healthy individuals, it could be possible that a
small chronic increase in ROS triggers a constant activation of
antioxidant defenses. Indeed, as shown after measuring GSH
in these cells, the carrier showed a greater amount compared
to control (Figure 2E; 150.2 ± 29.35; ∗p < 0.05). The level
of GSH in patients instead was decreased, but omav was able
to restore the levels within the cells (Figure 2E; Patient 1
72.44 ± 8.2; Patient 1_omav 111.6 ± 15.83; ∗p < 0.05; Patient 2
51.86 ± 8.24, Patient 2_omav 116.7 ± 33.25; ∗p < 0.05; Patients
untreated compared to Control: ∗∗∗p < 0.0005). These results
show that omav is able to increase the antioxidant defenses
in FRDA fibroblasts, decrease mitochondrial ROS production
and lipid peroxidation, and hence protect against oxidative
stress.
Omaveloxolone Ameliorates Mitochondrial
Energy Imbalance
The lack of frataxin results in hypersensitivity to oxidative
stress and contributes to the mitochondrial pathophysiology.
Mitochondrial dysfunction plays an important role in FRDA
FIGURE 5 | Interaction between omav and Nrf2 pathway. The
Nrf2 transcription factor in cells is regulated by ubiquitination and proteosomal
degradation through Keap1 protein. The increase of reactive oxygen species
(ROS) in cell promotes its translocation to the nucleus where it binds the
antioxidant responsive elements (ARE) favoring the transcription of the genes
involved in the antioxidant response. Omav is a Nrf2 inducer promotes its
activity by inhibiting Keap1 ubiquitinating activity and preventing
Nrf2 degradation.
pathophysiology and given the recently recognized role of
Nrf2 in regulating mitochondrial metabolism and function,
as reviewed by Esteras et al. (2016) and Holmström et al.
(2016), we investigated whether omav could also prevent possible
mitochondrial defects in fibroblasts. First we measured the
basal levels of ∆Ψm and found that, although there was a
trend, patient fibroblasts were not significantly depolarized
at steady state compared to controls (Figure 3A; Carrier
96.27 ± 4.09, Patient 1 86.16 ± 3.9, Patient 2 90.90 ± 8.39,
Patient 1_omav 109.4 ± 18.69 Patient 2_omav 94.23 ± 9.9;
p > 0.05). Therefore, we challenged human fibroblasts with
1 mM H2O2 for 2 h and investigated whether omav could
be protective to mitochondrial pathophysiology. Indeed, the
presence of H2O2 disrupted the ability of the electron
respiratory chain (ETC) to maintain the ∆Ψm only in patients’
fibroblasts but not in control cells, after administration of
oligomycin (Figure 3B). The ∆Ψm was analyzed in de-quench
mode, where an increase of fluorescence shows depolarization.
Untreated patient cells did not show depolarization, while,
H2O2 treated cells did show a great increase in fluorescence.
Interestingly, omav significantly protected the mitochondria
from this detrimental effect (Figures 3B,C). Figure 3C
summarizes the response to oligomycin in percentage (Patient
1_H2O2 203.5 ± 23.06, Patient 1_omav_H2O2 148 ± 30.9;
∗∗p < 0.005). We can conclude that under induced oxidative
stress, FRDA cells show a defect in the maintenance of ∆Ψm
but omav protected the cells from the H2O2 detrimental
effect.
H2O2 Induced Cell Death Was Prevented
by Omaveloxolone
FRDA is characterized by atrophy in DRG and cerebellum,
which is the result of neuronal death, therefore it is important
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to determine the efficacy of potential therapeutic drugs
preventing cell death. We assessed cell death in patient
fibroblasts by PI staining. Patients’ fibroblasts presented
hypersensitivity to H2O2 as shown by higher levels of
cell death, which was promptly prevented by omav pre-
incubation, confirming the efficacy of the drug (Figure 4;
Carrier_H2O2 15.67 ± 5.4, Carrier_omav_H2O2 5.7 ± 4.3,
Patient 1_H2O2 21.11 ± 1.428, Patient 1_omav_ H2O2; Patient
2_H2O2 39.95 ± 8.97, Patient 2_omav_ H2O2 2.297 ± 0.75;
∗∗∗p< 0.0005).
DISCUSSION
This work sought to understand the potential beneficial
effect of omav in CGNs and in fibroblasts from FRDA
patients. Mitochondrial dysfunction and oxidative stress are
two of the major dysfunctional outcomes shared between
neurodegenerative disorders. In particular, in FRDA, both
of these detrimental processes contribute significantly to its
pathophysiology. Nrf2, a transcription factor which regulates
the antioxidant response during oxidative stress, seems to be
disrupted, not only in DRG but also in fibroblasts of FRDA
models (Paupe et al., 2009; Shan et al., 2013). Moreover,
Nrf2 pathway has also an important role in regulating
mitochondrial bioenergetics and function (Dinkova-Kostova
et al., 2015, 2017). Hence, we have investigated the protective
effect of omav, an Nrf2 inducer, in CGNs from the KIKO
and YG8R mouse models and FRDA patient fibroblasts. Omav
promotes Nrf-2 activity by inhibiting Keap 1 ubiquitinating
activity and preventing Nrf2 degradation (Figure 5). By
looking at the NADH redox state and pool we found that
the pool was low and the redox state was high compared
to control. These two parameters demonstrate that there
is a lack of mitochondrial substrates for respiration and
that Complex I is also inhibited, in all the models tested.
Together with our previous experiments on neurons (Abeti
et al., 2016), we can conclude that FRDA could be listed
on the Complex I deficient diseases. We found that the
level of lipid peroxidation and mitochondrial ROS were
increased and that GSH was reduced in patient’s fibroblasts
at steady state. Previously it has been observed that patient’s
fibroblasts fail to activate Nrf2 which consequently reduces
the expression of superoxide dismutase 1 and 2 (SOD1/2),
Glutathione S-transferase P (GSTP1; crucial for the formation
of GSH) and NAD(P)H dehydrogenase (quinone) 1 (NQO1),
causing a greater susceptibility to oxidative stress (Paupe et al.,
2009). Therefore, we monitored the ability of mitochondria
to maintain their membrane potential, stimulating the cells
with an oxidant, H2O2, and found that the maintenance of
∆Ψm was impaired, showing a marked depolarization after
oligomycin addition. This implies that the complexes of the
ETC were not working properly in FRDA fibroblasts. Disruption
in the maintenance of ∆Ψm has been established to be one
of the effects of frataxin decrease in neurons and mouse
fibroblasts (Abeti et al., 2015, 2016). However, by adding
omav for 24 h prior the beginning of the experiments,
∆Ψm was maintained correctly. More importantly, we showed
that omav reverses this pathophysiological phenotype, in
agreement with previous findings with this compound in other
neurodegenerative disorders (Bartolome et al., 2017; Dinkova-
Kostova et al., 2017). Oxidative stress and mitochondrial
dysfunction are a cause of cell death and we finally studied
TABLE 2 | Previous and current work on omaveloxolone (omav).
Cellular models Omav impact on cell functions References
Mouse and rat keratinocytes NRF2 translocation, m-RNA level of Nrf2, Nqol and glutathione
protein expression.
Reisman et al. (2014a,b)
Human Keratinocytes mRNA expression of many cytoprotective Nrf2 target genes, Protein
expression ofNqo1.
Reisman et al. (2015)
Macrophages Nitrite (NO2− ) concentrations in the media were measured by Griess
reaction and cell viability; m-RNA expression of many cytoprotective
Nrf2 target genes (Nqo1, Txnrd1, and Gclc) and m-RNA level of
pro-inflammatory genes (Nos2, Ptgs2, cc12, and cc15).
Probst et al. (2015)
Human tumor cell lines Check Caspase-3 and caspase-9 cleavage by western blot, m-RNA
expression of many cytoprotective Nrf2 target genes (Nqo1, Txnrd1,
and Gclc).
Probst et al. (2015)
Diabetic wounds (dorsal mice skin) Time of diabetic wounds closure, level of ROS with live imaging, level
of expression of Nrf2 target antioxidant genes, Nqo1, MnSOD, heme
oxygenase 1 (HO-1), glutathione S-transferase (GST), and glutamate
cysteineligase (GCL).
Rabbani et al. (2018)
Primary midbrain neurons of PINKI mouse model
(Parkinson Disease)
Mitochondrial Membrane Potential, Cell death. Dinkova-Kostova et al. (2017)
Neuronal-glial co-cultures/Kainic acid induced
status epilepticus epilepsy rat model
Level of ROS, Mitochondrial membrane potential, cell death, seizure
activity, ATP production.
Shekh-Ahmad et al. (2018)
Human p62 fibroblasts (ALS/FTD), 1362 KD
SH-SY5Y cells
Mitochondrial membrane potential, NADH. Bartolome et al. (2017)
Human FRDA patients’ fibroblasts Level of ROS, lipid peroxidation, mitochondrial membrane potential,
GSH, NADH, cell death.
Current article results
Cerebellar granule neurons (FRDA like mouse
models)
NADH Current article results
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whether omav could prevent cell death in patients’ fibroblasts.
Indeed, omav successfully prevented the death of fibroblasts
after an oxidative insult with H2O2. From our experiments,
we can conclude that patients’ fibroblasts present with increase
of oxidative stress and this causes greater susceptibility to the
administration of oxidants. Omav is effective in counteracting
the detrimental effects on the pathophysiology of FRDA,
preventing oxidative stress and mitochondrial dysfunction.
Moreover, CGNs from FRDA-like mouse models, showing
complex I inhibition, were efficiently protected by omav.
Previous works on omav demonstrate that this compound
triggers the Nrf2 pathway and show that it is cytoprotective
(Reisman et al., 2014a,b, 2015; Probst et al., 2015; Rabbani et al.,
2018; Table 2). This together with our findings makes omav a
very good candidate for treatment in this currently incurable
disease.
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